Are you Dr. Volm?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 69 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
160 E 34th St
4th Fl.
New York, NY 10016Phone+1 212-731-5433
Summary
- Dr. Matthew Volm, MD is an oncologist in New York, New York. He is currently licensed to practice medicine in New York.
Education & Training
University of Illinois College of Medicine at ChicagoFellowship, Hematology and Medical Oncology, 1993 - 1996
NYU Grossman School of MedicineResidency, Internal Medicine, 1989 - 1992
University of Minnesota Medical SchoolClass of 1989
Certifications & Licensure
NY State Medical License Active through 2014
Awards, Honors, & Recognition
- Top Doctors: New York Metro Area Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma Start of enrollment: 1999 Jul 26
- Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed Start of enrollment: 2000 Aug 01
- Liposomal Doxorubicin and Trastuzumab in Treating Women With Advanced Breast Cancer Start of enrollment: 2000 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- 24 citationsFeasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast ...Eleni Andreopoulou, Darci Gaiotti, Eugene Kim, Matthew Volm, Ruth Oratz
Clinical Breast Cancer. 2007-08-01 - 49 citationsConcurrent paclitaxel and radiation therapy for breast cancer.Silvia C. Formenti, W. F. Symmans, Matthew Volm, Kristin A. Skinner, Deirdre Cohen
Seminars in Radiation Oncology. 1999-04-01 - 246 citationsDevelopment of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.Sandra Demaria, Matthew Volm, Richard L. Shapiro, Herman Yee, Ruth Oratz
Clinical Cancer Research. 2001-10-01
Grant Support
- Rhumab HER2 In Relapsed Breast Cancer Patients W/ 2 Prior Chemotherapy RegimensNational Center For Research Resources1999–2002
- LAB Study To Evaluate Paclitaxels Cellular &Molecular Effects In Breast CancerNational Center For Research Resources1999–2002
- Multimodality Therapy For Locally Advanced Breast CancerNational Center For Research Resources1998–2002
- Doxil, Cyclophosphamide, Vincristine And Prednisone For AIDS LymphomaNational Center For Research Resources1998–2002
- Temodal In Patients With Advanced MalignanciesNational Center For Research Resources2000
- Serum HER 2 Ecdo Antigen In Breast CancerNational Center For Research Resources2000
- Herceptin, Paclitaxel In Breast Cancer W/ HER2 ExpressioNational Center For Research Resources2000
